Copy to clipboard 
HydroCision announced that it was granted U.S. Patent No. 11,278,305, Selective Tissue Removal Treatment Device, for the TenJet device. TenJet is believed to be the first patented device allowing for the targeted removal of tendon tissue.
The patent covers the application of HydroCision’s FluidJet technology for the treatment of chronic tendon pain. TenJet’s tissue selectivity feature allows the removal of pathologic tendon tissue while preserving adjacent healthy tendons, enabling quicker and less painful post-procedure rehabilitation.
The TenJet device used for targeted, selective removal of degenerative, pathologic tendon tissue. Photo courtesy of HydroCision.
TenJet extends the tools available to physicians to address degeneration and calcifications within tendons across all joints. Procedures using TenJet are minimally invasive and can be performed in an outpatient setting. The entire procedure is conducted using real-time ultrasound image-guidance.
“Design and development of innovative medical devices can take multiple years of dedicated effort with the ultimate validation coming from its users. It has been truly rewarding to hear from physicians and patients that have benefitted from TenJet. No matter which tendon it is, after years of pain and multiple failed treatments, patients are finally able to return to a normal life,” Alain Tranchemontagne, CEO, HydroCision, said.
